Mr. Hugh MacNaught reports

VENTRIPOINT EXPANDS ADVISORY BOARD WITH ADDITION OF ULTRASOUND AI EXECUTIVE

Ventripoint Diagnostics Ltd. has increased the depth of its commercial experience with the addition of Stuart Gall to the company's business advisory board to provide advice and guidance on the commercialization of Ventripoint's artificial-intelligence-powered, heart-scanning technology by hospitals and clinics around the world.

With its proprietary VMS+ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption.

A seasoned health technology executive, Mr. Gall is chief executive officer of Intelligent Ultrasound (AIM: MED), a company that develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity simulators for the ultrasound training market. Based in the United Kingdom and United States, Intelligent Ultrasound has a portfolio of market leading products used in approximately 500 medical institutions around the world. Previously, Mr. Gall was a joint founder and executive director of Fusion IP PLC, an AIM-listed intellectual property (IP) commercialization company, that was acquired for 103 million pounds sterling. He has over 25 years experience in both small company start-ups and public companies and previously worked at British Airways PLC, The Promotions Partnership Ltd., Anvil Ltd. and Toad PLC (now 21st Century Technology PLC).

"Stuart has demonstrated the ability to repeatedly build successful technology ventures," said Ventripoint's chief executive officer Hugh MacNaught. "With VMS+ 4.0 being cleared for sale in multiple markets, Mr. Gall's insights and experience and will be extremely helpful in advancing Ventripoint toward commercial success."

Added Mr. Gall: "Ventripoint's VMS+ offers an AI enhancement to echocardiography that provides a fast, inexpensive and accessible alternative to MRIs. This product enables active cardiology practices to provide more timely management of the needs of patients with complex and challenging conditions."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.